Our Values
-
Innovation: Pioneering advancements in RNA technology to unlock new possibilities in healthcare.
-
Integrity: Upholding the highest standards of ethics and transparency in every aspect of our work.
-
Collaboration: Fostering partnerships to accelerate scientific discovery and therapeutic breakthroughs.
-
Patient-Centricity: Dedicated to developing therapies that are as unique as the patients they help.
-
Impact: We innovate relentlessly, operate with integrity, and strive for impactful solutions in all we do.
Who is Helixomer?
Helixomer is a preclinical RNA nanodrug company in Research Triangle Park, NC, developing a fully synthetic, reversible anticoagulant to replace heparin and protamine in acute critical care.
Our lead program, Hex01 (anticoagulant) and Hex02 (reversal agent), addresses heparin's core limitations: immune reactions, bleeding risk, a porcine-derived supply chain vulnerable to shortage and protamine complications. Hex01 and Hex02are fully synthetic, making them viable for patients who cannot use animal-derived medicines for religious or ethical reasons.
Our RNA Origami (RNAO) platform extends aptamer half-life without incorporating polyethylene glycol, achieving a 2 to 3.5-hour half-life in rabbits.
Helixomer is advancing through IND-enabling studies with Kymanox Venture Studios, backed by $2.5 million (USD) in nondilutive funding, including a $2 million (USD) Direct-to-Phase II NIH SBIR. Our pre-seed round is now open.
Our Mission
Helixomer's mission is to create more effective, smarter, and safer RNA medicines powered by our patented RNA Origami (RNAO) functionalized with aptamers. We build around the standard that clinicians and patients need most: control without compromise.
Our Vision
To define the future of RNA medicines, starting with the controllable, reversible anticoagulant and matched reversal agent that acute critical care has needed for decades.
